Evaluation of Correlation Between the Pharmacogenetic Profiles of Risperidone Treated Psychiatry Patients with Plasma and Urine Concentration of Risperidone and its Active Moiety 9-OH Risperidone Determined with Optimized Bioanalytical LC Method

1. Gardner ER, Figg WD, Sparreboom A., Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2.Current Pharmacogenomics 11/2006; 4(4): 331–344.10.2174/157016006778992778Search in Google Scholar

2. Aichhorn W, Weiss U, Marksteiner J, Kemmler G, Walch T, Zernig G, Stelzig-Schoeler R, Stuppaeck C, Geretsegger C. Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol. 2005 Jul; 19(4): 395–401. Laysen JE et al., 1988–9.10.1177/02698811050533061598299515982995Open DOISearch in Google Scholar

3. Rafaniello C, Sessa M, Bernardi FF, Pozzi M, Cheli S, Cattaneo D, Baldelli S, Molteni M, Bernardini R, Rossi F, Clementi E, Bravaccio C, Radice S, Capuano A. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics J. 2018 May 22; 18(3): 422–430.10.1038/tpj.2017.3828719598Open DOISearch in Google Scholar

4. Vandenberghe F, Guidi M, Choong E, von Gunten A, Conus P, Csajka C, Eap CB. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. Clin Pharmacokinet. 2015 Dec; 54(12): 1259–72.10.1007/s40262-015-0289-826129906Search in Google Scholar

5. Bork JA, Rogers T, Wedlund PJ, de Leon J. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry. 1999 Jul; 60(7): 469–76.10.4088/JCP.v60n0709Search in Google Scholar

6. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005 Jan; 66(1): 15–27.10.4088/JCP.v66n0103Search in Google Scholar

7. de Leon J, Sandson NB, Cozza KL. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II. Psychosomatics. 2008 Jul-Aug; 49(4): 347–61.10.1176/appi.psy.49.4.34718621942Open DOISearch in Google Scholar

8. Wang JS, DeVane CL, Gibson BB, Donovan JL, Markowitz JS, Zhu HJ. Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology (Berl). 2006 Jan; 183(4): 490–9.10.1007/s00213-005-0209-y16283256Search in Google Scholar

9. Baumann P, Hiemke C, Ulrich S, Gaertner I, Rao ML, Eckermann G, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Riederer P, Zernig G. Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. Ther Drug Monit. 200410.1097/00007691-200404000-000141522815915228159Open DOISearch in Google Scholar

10. Seto K, Dumontet J, Ensom MH.Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? Ther Drug Monit. 2011 Jun; 33(3): 275–83.10.1097/FTD.0b013e3182126d8321436762Search in Google Scholar

11. Jovanović N, Božina N, Lovrić M, Medved V, Jakovljević M, Peleš AM. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol. 2010 Nov; 66(11): 1109–17.10.1007/s00228-010-0850-120563569Search in Google Scholar

12. Naumovska Z, Brezovska K, Tonic-Ribarska J, Kapedanovska Nestorovska A, Sterjev Z, Grozdanova A, Filipce A, Suturkova Lj. Optimization of bioanalytical LC method for simultaneous determination of risperidone and its active metabolite 9-OH risperidone in human plasma and urine. IOSR Journal of Pharmacy www.iosrphr.org (e)-ISSN: 2250-3013, (p) - ISSN: 2319 – 4219 Volume 7, Issue 12 Version. 1 (December 2017), PP. 54–64.Search in Google Scholar

13. Cabovska B, Cox SL, Vinks AA. Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1; 852(1-2): 497–504. Epub 200710.1016/j.jchromb.2007.02.007276161917344104Search in Google Scholar

14. Foroutan, S.M., Zarghi, A., Shafaati A. (2006) Foroutan, S.M., Zarghi, A., Shafaati A. Rapid high performance liquid chromatographic determina tion of risperidone in human plasma. Iranian Journal of Pharmaceutical Research. (2006) 1, 37–40.Search in Google Scholar

15. Dean L. Clozapine Therapy and CYP2D6, CYP1A2, and CYP3A4 Genotypes. 2016 Jun 8. In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012. Available from http://www.ncbi.nlm.nih.gov/books/NBK367795/PubMed PMID: 28520368.Search in Google Scholar

16. Mannheimer B, Holm J, Koukel L, Bertilsson L, Osby U, Eliasson E. Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients. Eur J Clin Pharmacol. 2014 Jun; 70(6): 695–9.10.1007/s00228-014-1664-324643635Search in Google Scholar